U.S. markets closed

Helix BioPharma Corp. (HBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.8800+0.0500 (+6.02%)
At close: 3:37PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8300
Open0.8700
Bid0.8600 x 0
Ask0.8800 x 0
Day's Range0.8700 - 0.8800
52 Week Range0.2500 - 1.1600
Volume5,209
Avg. Volume14,503
Market Cap124.197M
Beta (5Y Monthly)-0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0540
Earnings DateJun 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management
      ACCESSWIRE

      Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management

      RICHMOND HILL, ON / ACCESSWIRE / June 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer ("CEO"), Chief Scientific Officer ("CSO") and member of the Board, effective September 1, 2021.

    • Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants
      ACCESSWIRE

      Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants

      RICHMOND HILL, ON / ACCESSWIRE / June 24, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has appointed Marcum LLP as the Company's new auditor, replacing BDO Canada LLP.

    • HBP.TO: Third Quarter Fiscal Year 2021 Operational and Financial Results
      Zacks Small Cap Research

      HBP.TO: Third Quarter Fiscal Year 2021 Operational and Financial Results

      By John Vandermosten, CFA TSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT Helix BioPharma Corp. (TSX:HBP.TO) (OTC:HBPCF) reported 3Q:21 financial and operational results and submitted its SEDAR filings on June 14, 2021. During 3Q:21, the three months ended April 30, 2021, Helix appointed Dr. Frank Gary Renshaw to the Scientific Advisory Board, and extended the exercise period for